دورية أكاديمية
Restoration of ARID1A Protein in ARID1A-deficient Clear Cell Carcinoma of the Ovary Attenuates Reactivity to Cytotoxic T Lymphocytes.
| العنوان: | Restoration of ARID1A Protein in ARID1A-deficient Clear Cell Carcinoma of the Ovary Attenuates Reactivity to Cytotoxic T Lymphocytes. |
|---|---|
| المؤلفون: | Tsunematsu R; Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan.; Department of Obstetrics and Gynecology, Sapporo Medical University School of Medicine, Sapporo, Japan., Murai A; Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan., Mizue Y; Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan., Kubo T; Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan., Mariya T; Department of Obstetrics and Gynecology, Sapporo Medical University School of Medicine, Sapporo, Japan., Morita R; Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan., Murata K; Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan., Kanaseki T; Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan., Tsukahara T; Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan., Hirohashi Y; Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan hirohash@sapmed.ac.jp., Saito T; Department of Obstetrics and Gynecology, Sapporo Medical University School of Medicine, Sapporo, Japan., Torigoe T; Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan torigoe@sapmed.ac.jp. |
| المصدر: | Cancer genomics & proteomics [Cancer Genomics Proteomics] 2024 Jul-Aug; Vol. 21 (4), pp. 414-420. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: International Institute of Anticancer Research Country of Publication: Greece NLM ID: 101188791 Publication Model: Print Cited Medium: Internet ISSN: 1790-6245 (Electronic) Linking ISSN: 11096535 NLM ISO Abbreviation: Cancer Genomics Proteomics Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Kapandriti, Attiki, Greece : International Institute of Anticancer Research, [2004]- |
| مواضيع طبية MeSH: | Ovarian Neoplasms*/immunology , Ovarian Neoplasms*/genetics , Ovarian Neoplasms*/pathology , Ovarian Neoplasms*/metabolism , Transcription Factors*/genetics , Transcription Factors*/metabolism , DNA-Binding Proteins*/genetics , DNA-Binding Proteins*/metabolism , Adenocarcinoma, Clear Cell*/pathology , Adenocarcinoma, Clear Cell*/genetics , Adenocarcinoma, Clear Cell*/immunology , Adenocarcinoma, Clear Cell*/metabolism , T-Lymphocytes, Cytotoxic*/immunology, Humans ; Female ; Cell Line, Tumor ; Antigens, Neoplasm/genetics ; Antigens, Neoplasm/metabolism ; Antigens, Neoplasm/immunology ; HLA-A2 Antigen/genetics ; HLA-A2 Antigen/immunology ; HLA-A2 Antigen/metabolism ; Membrane Proteins |
| مستخلص: | Background/aim: Clear cell carcinoma is a prevalent histological type of ovarian cancer in East Asia, particularly in Japan, known for its resistance to chemotherapeutic agents and poor prognosis. ARID1A gene mutations, commonly found in ovarian clear cell carcinoma (OCCC), contribute to its pathogenesis. Recent data revealed that the ARID1A mutation is related to better outcomes of cancer immunotherapy. Thus, this study aimed to investigate the immunotherapy treatment susceptibility of OCCC bearing ARID1A mutations. Materials and Methods: Expression of ARID1A was analyzed using western blotting in ovarian cancer cell lines. OCCC cell lines JHOC-9 and RMG-V were engineered to overexpress NY-ESO-1, HLA-A*02:01, and ARID1A. Sensitivity to chemotherapy and T cell receptor-transduced T (TCR-T) cells specific for NY-ESO-1 was assessed in ARID1A-restored cells compared to ARID1A-deficient wild-type cells. Results: JHOC-9 cells and RMG-V cells showed no expression of ARID1A protein. Overexpression of ARID1A in JHOC-9 and RMG-V cells did not impact sensitivity to gemcitabine. While ARID1A overexpression decreased sensitivity to cisplatin in RMG-V cells, it had no such effect in JHOC-9 cells. ARID1A overexpression reduced the reactivity of NY-ESO-1-specific TCR-T cells, as observed by the IFNγ ESLIPOT assay. Conclusion: Cancer immunotherapy is an effective approach to target ARID1A-deficient clear cell carcinoma of the ovary. (Copyright © 2024, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.) |
| References: | Cancer Immunol Immunother. 2022 Apr;71(4):795-806. (PMID: 34405274) Anticancer Res. 2023 Aug;43(8):3401-3410. (PMID: 37500149) CA Cancer J Clin. 2022 Jan;72(1):7-33. (PMID: 35020204) Sci Transl Med. 2020 Jun 17;12(548):. (PMID: 32554706) J Clin Invest. 2020 May 1;130(5):2712-2726. (PMID: 32027624) Cancers (Basel). 2021 Apr 07;13(8):. (PMID: 33917230) Annu Rev Pathol. 2020 Jan 24;15:467-492. (PMID: 31977292) Cancer Discov. 2021 Jun;11(6):1562-1581. (PMID: 33451982) J Pathol. 2023 Jul;260(3):304-316. (PMID: 37138382) Cancers (Basel). 2023 Dec 27;16(1):. (PMID: 38201563) N Engl J Med. 2010 Oct 14;363(16):1532-43. (PMID: 20942669) Cancer Res. 2011 Nov 1;71(21):6718-27. (PMID: 21900401) Gynecol Oncol. 2021 Sep;162(3):679-685. (PMID: 34272091) Gynecol Oncol. 2019 Jun;153(3):589-596. (PMID: 30905436) Cancer Res. 2016 Jan 15;76(2):227-38. (PMID: 26637667) Mod Pathol. 2012 Apr;25(4):615-24. (PMID: 22157930) Gynecol Oncol. 2019 Dec;155(3):489-498. (PMID: 31604667) J Immunother Cancer. 2020 Feb;8(1):. (PMID: 32111729) Nat Med. 2018 May;24(5):556-562. (PMID: 29736026) J Immunol. 2011 May 1;186(9):5173-83. (PMID: 21441454) Anticancer Res. 2023 Apr;43(4):1477-1484. (PMID: 36974807) Cancer Med. 2023 Feb;12(4):4605-4615. (PMID: 36200687) |
| فهرسة مساهمة: | Keywords: ARID1A; Ovarian cancer; clear cell carcinoma; cytotoxic T lymphocytes |
| المشرفين على المادة: | 0 (Transcription Factors) 0 (ARID1A protein, human) 0 (DNA-Binding Proteins) 0 (CTAG1B protein, human) 0 (Antigens, Neoplasm) 0 (HLA-A2 Antigen) 0 (Membrane Proteins) |
| تواريخ الأحداث: | Date Created: 20240629 Date Completed: 20240629 Latest Revision: 20240722 |
| رمز التحديث: | 20240722 |
| مُعرف محوري في PubMed: | PMC11215429 |
| DOI: | 10.21873/cgp.20460 |
| PMID: | 38944423 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1790-6245 |
|---|---|
| DOI: | 10.21873/cgp.20460 |